State Street
KROS icon

State Street’s Keros Therapeutics KROS Stock Holding History

State Street’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.79M Sell
541,193
-20,537
-4% -$229K ﹤0.01% 2939
2026
Q1 		$6.2M Sell
561,730
-514,263
-48% -$7.94M ﹤0.01% 2850
2025
Q4 		$21.9M Sell
1,075,993
-226,985
-17% -$3.98M ﹤0.01% 2218
2025
Q3 		$20.6M Sell
1,302,978
-81,276
-6% -$1.2M ﹤0.01% 2227
2025
Q2 		$18.5M Buy
1,384,254
+81,715
+6% +$1.1M ﹤0.01% 2231
2025
Q1 		$13.3M Buy
1,302,539
+99,156
+8% +$1.15M ﹤0.01% 2355
2024
Q4 		$19M Buy
1,203,383
+89,793
+8% +$4.67M ﹤0.01% 2254
2024
Q3 		$64.7M Sell
1,113,590
-107,786
-9% -$5.32M ﹤0.01% 1568
2024
Q2 		$55.8M Sell
1,221,376
-341,519
-22% -$18.4M ﹤0.01% 1617
2024
Q1 		$103M Buy
1,562,895
+508,528
+48% +$30.2M ﹤0.01% 1282
2023
Q4 		$41.9M Buy
1,054,367
+152,367
+17% +$4.78M ﹤0.01% 1798
2023
Q3 		$28.8M Sell
902,000
-113,903
-11% -$4.25M ﹤0.01% 1948
2023
Q2 		$40.8M Buy
1,015,903
+71,744
+8% +$3.15M ﹤0.01% 1792
2023
Q1 		$40.3M Sell
944,159
-23,979
-2% -$1.21M ﹤0.01% 1794
2022
Q4 		$46.5M Buy
968,138
+34,626
+4% +$1.62M ﹤0.01% 1689
2022
Q3 		$35.1M Sell
933,512
-57,240
-6% -$1.98M ﹤0.01% 1850
2022
Q2 		$27.4M Buy
990,752
+307,105
+45% +$13.5M ﹤0.01% 2024
2022
Q1 		$37.2M Buy
683,647
+28,655
+4% +$1.47M ﹤0.01% 1940
2021
Q4 		$38.3M Sell
654,992
-22,276
-3% -$1.11M ﹤0.01% 1999
2021
Q3 		$26.8M Sell
677,268
-1,710
-0.3% -$60.9K ﹤0.01% 2268
2021
Q2 		$28.8M Sell
678,978
-44,845
-6% -$2.43M ﹤0.01% 2266
2021
Q1 		$44.6M Buy
723,823
+297,732
+70% +$18.9M ﹤0.01% 1819
2020
Q4 		$30.1M Buy
426,091
+326,865
+329% +$20.6M ﹤0.01% 1979
2020
Q3 		$3.83M Buy
99,226
+14,215
+17% +$564K ﹤0.01% 2915
2020
Q2 		$3.19M Buy
+85,011
New +$2.62M ﹤0.01% 2990

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

State Street's KROS Position: Q2 2026 in Review

State Street reduced its Keros Therapeutics (KROS) stake by 3.7% in Q2 2026, selling an estimated $229K and leaving 541,193 shares worth $5.79M. The position accounts for ﹤0.01% of the portfolio, ranked #2939.

State Street first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $103M in Q1 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • State Street held 541,193 shares of Keros Therapeutics worth $5.79M as of Q2 2026.
  • State Street sold 20,537 Keros Therapeutics shares in Q2 2026, an estimated $229K.
  • Keros Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2939 holding.
  • State Street first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • State Street's Keros Therapeutics position peaked at $103M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.